Auto Draft

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is one of the 10 Stocks Notching Impressive Double-Digit Gains.

Teva Pharmaceutical rallied for a third consecutive day on Wednesday, climbing 11.89 percent to close at $35.38 apiece, as investors took heart from its strong earnings performance in the first quarter of the year.

In an updated report, Teva Pharmaceutical Industries Ltd (NYSE:TEVA) said that attributable net income soared by 72 percent to $369 million from $214 million in the same period last year, on the back of a 25.6 percent jump in operating income to $652 million versus $519 million year-on-year.

For illustration purposes only. Photo by Pietro Jeng on Pexels

Revenues inched up by 2.3 percent to $3.98 billion from $3.89 billion, amid portfolio growth and disciplined execution, even with lower revenues lenalidomide capsules due to increased generic competition in the US.

For this year, Teva Pharmaceutical Industries Ltd (NYSE:TEVA) maintained its revenue outlook for 2026, at $16.4 billion to $16.8 billion.

However, it notably lowered its guidance for other key metrics, including operating income, adjusted EBITDA, and diluted earnings per share (EPS).

Operating income was cut to a range of $3.8 billion to $4 billion, versus the $4.55 billion to $4.8 billion range prior.

Adjusted EBITDA was reduced to $4.23 billion to $4.53 billion, versus $5 billion to $5.3 billion previously.

Diluted EPS was pegged to end at $1.91 to $2.11, lower than the $2.57 to $2.77 previously.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.